PharmaTox
The PharmaTox Strategic Research Initiative aims to generate novel insight on effects of pharmaceuticals on human neurotoxicity and neurodevelopment.
PharmaTox was established January 1st 2015 as a prioritized research initiative supported by the Faculty of Mathematics and Natural Sciences.
The research projects within PharmaTox involve specialists in neurotoxicology, pharmacology, teratology, statistics, bioinformatics, epigenetics and epidemiology.
News
-
Prof. Nordeng appointed by European Commission as independent scientific expert in PRAC
Dec. 4, 2018 1:55 PM
The Pharmacovigilance Risk Assessment Committee (PRAC) is the European Medicines Agency's (EMA) committee responsible for assessing and monitoring the safety of human medicines.
-
Successful UiO:LifeScience projects in PharmaTox!
Nov. 23, 2018 12:03 PM
-
PhD student Nils Anders Labba at NRSN conference
Nov. 1, 2018 2:35 PM
PharmaTox PhD student Nils Anders Labba was awarded two prizes at the annual conference of the Norwegian Research School in Neuroscience (NRSN) in September.
-
UiOLifeScience supports internalization for two PharmaTox researchers!
Sep. 17, 2018 10:02 AM
Life sciences represent the largest priority area of the University of Oslo (UiO) and aim to support multidisciplinary collaboration and research mobility. Dr. Angela Lupattelli and PhD student Anna S. Frank in PharmaTox have both been granted funding by UiOLifeScience to support international project collaborations.
-
PharmaTox researchers at ICPE in Prague
Sep. 10, 2018 12:59 PM
Several PharmaTox researchers attended the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management August 22-26 in Prague which was organized by the International Society of PharmacoEpidemiology (ISPE).
